Comparative Pharmacology
Head-to-head clinical analysis: ANTURANE versus SULFINPYRAZONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTURANE versus SULFINPYRAZONE.
ANTURANE vs SULFINPYRAZONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Uricosuric agent; inhibits renal tubular reabsorption of uric acid, increasing uric acid excretion and lowering serum urate levels.
Competitive inhibitor of tubular organic anion transport, increasing uric acid excretion; also inhibits platelet aggregation.
200-400 mg orally twice daily
100-200 mg orally twice daily, initially, then increase to 200-400 mg twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 4–6 hours for the parent drug; active sulfide metabolite has a half-life of 12–16 hours. Clinically, twice-daily dosing maintains therapeutic levels.
Clinical Note
moderateSulfinpyrazone + Teriflunomide
"The metabolism of Teriflunomide can be decreased when combined with Sulfinpyrazone."
Clinical Note
moderateSulfinpyrazone + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Sulfinpyrazone."
Clinical Note
moderateSulfinpyrazone + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Sulfinpyrazone."
Clinical Note
moderateSulfinpyrazone + Cyclosporine
2-5 hours (terminal elimination half-life; prolonged in renal impairment to up to 10 hours)
Renal excretion: approximately 50% of the dose as unchanged drug and its active sulfide metabolite via glomerular filtration and tubular secretion; biliary/fecal: ~30%, primarily as metabolites.
Renal: ~90% (50% unchanged, 50% as glucuronide and other metabolites); Biliary/fecal: ~10%
Category C
Category A/B
Uricosuric
Uricosuric
"The serum concentration of Cyclosporine can be decreased when it is combined with Sulfinpyrazone."